Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) saw a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 11,600 shares, a growth of 152.2% from the September 30th total of 4,600 shares. Based on an average daily trading volume, of 12,300 shares, the short-interest ratio is presently 0.9 days.
Genenta Science Stock Performance
NASDAQ GNTA traded down $0.13 during trading on Friday, hitting $5.22. The company's stock had a trading volume of 8,137 shares, compared to its average volume of 29,437. Genenta Science has a 52 week low of $2.20 and a 52 week high of $7.28. The firm has a 50 day moving average price of $4.49 and a 200 day moving average price of $3.87.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a "buy" rating and issued a $25.00 target price on shares of Genenta Science in a report on Wednesday, October 2nd.
Get Our Latest Stock Report on Genenta Science
Institutional Trading of Genenta Science
A hedge fund recently bought a new stake in Genenta Science stock. AlTi Global Inc. acquired a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 200,288 shares of the company's stock, valued at approximately $621,000. AlTi Global Inc. owned 1.10% of Genenta Science as of its most recent filing with the Securities and Exchange Commission. 15.13% of the stock is owned by institutional investors and hedge funds.
Genenta Science Company Profile
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Featured Articles
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
